News
22h
MedPage Today on MSNFDA Lifts Pause on Chikungunya Vaccine in Older Adults, With Revised Labeling
"Based on the available data, and its benefit-risk assessment, FDA has removed the recommended pause in the use of Ixchiq in ...
3d
MedPage Today on MSNDid FDA Pick the Wrong COVID Vaccine Strain Last Season?
A separate Danish study showed that the two mRNA vaccines were also safe, with no increase in adverse events of special ...
Dr. Vinay Prasad is stepping down as the Food and Drug Administration’s top vaccine regulator after a brief tenure ...
Valneva SE ( NASDAQ: VALN) said on Thursday that the FDA has lifted its pause on the use of its chikungunya vaccine, Ixchiq, ...
9hon MSN
Are mRNA Vaccines Safe — and Should You Still Get a COVID Shot? Doctors on the Pros and Cons
RFK Jr. recently made major cuts to mRNA vaccine development research, questioning their safety. Should you still get the ...
Dr. Vinay Prasad, an oncologist who was a fierce critic of COVID vaccine and mask mandates, was appointed in May.
Dr. Vinay Prasad had been serving as the FDA's director of the Center for Biologics Evaluation and Research since May, and ...
The U.S. Food and Drug Administration's top vaccine official, Vinay Prasad, has left the agency after just three months as ...
The FDA has removed a pause in the use of Valneva’s chikungunya vaccine in older adults while tweaking the shot’s label with stricter language.
As part of a postmarketing requirement, Valneva will be initiating a study to assess the risk of severe chikungunya-like adverse reactions following administration of Ixchiq.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results